-
Biotech Events
274 events
Date Symbol Description Type Disease Designation Success Rating H1 2018 CNAT Conatus Pharmaceuticals (CNAT) Phase 2b Results of Emricasan for Liver Fibrosis
Phase 2b Results Other Fast Track, Orphan Drug H1 2018 RETA Reata Pharmaceuticals (RETA) Phase 3 Results of Bardoxolone Methyl for Pulmonary Arterial Hypertension
Phase 3 Results Cardiovascular Orphan Drug H2 2018 MACK Merrimack Pharmaceuticals (MACK) Phase 2 Results of Istiratumab (MM-141) for Front-Line Metastatic Pancreatic Cancer with High Serum Levels of Free IGF-1
Phase 2 Results Oncology Orphan Drug H2 2018 MACK Merrimack Pharmaceuticals (MACK) Phase 2 Results of Seribantumab (MM-121) for Non-Small Cell Lung Cancer
Phase 2 Results Oncology Fast Track -